Blog

Roberto Contieri: Great start to EAU 2025 with important session on treatment deintensification in low-grade bladder cancer

Roberto Contieri/X

Mar 25, 2025, 18:33

Roberto Contieri: Great start to EAU 2025 with important session on treatment deintensification in low-grade bladder cancer

Ashish M. Kamat, Professor and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, shared Roberto Contieri’s, Urologist at Humanitas University, post on X:

“Impressive how Roberto, early in his career, has developed significant expertise in the nuanced management of LG NMIBC, with a focused interest in patient-centered outcomes.

Full here.”

Quoting Roberto Contieri’s post:

“Great start to EAU25 with an important session on treatment deintensification in low-grade bladder cancer. Fantastic to see Ashish M. Kamat present the IBCG recommendations – a major step forward for personalized care.”

Uncover innovative insights into bladder cancer – dive deeper into our findings

Radiotherapy for Bladder Cancer: Types, Success Rate, Side Effects And More

Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More

NIAGARA Study Insights: Durvalumab and Chemotherapy in Bladder Cancer Treatment | Dr. Petros Grivas

Ashish M. Kamat bladder cancer cancer EAU 2025 Humanitas University IBCG MD Anderson Cancer Center OncoDaily Oncology Roberto Contieri urologic oncology

OncoDaily and Big Whig Media Announce Partnership: Global Oncology Media Leader Joins Forces with Premier Washington, D.C. Multimedia Powerhouse

Does Vaping Cause Lung Cancer? Myths and Facts

James Van Der Beek: Battle with Colorectal Cancer and Marriage Challenges During Treatment

FDA approval: Pembrolizumab for HER2 positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥1): KEYNOTE-811 Trial

Changing the Future of Adolescent and Young Adult Cancer Care